[{"Assets_0_Q2_USD":6225298.0,"CommonStockSharesOutstanding_0_Q2_shares":12035912.0,"EarningsPerShareBasic_1_Q2_USD":-0.09,"EarningsPerShareBasic_2_Q2_USD":-0.22,"EarningsPerShareDiluted_1_Q2_USD":-0.09,"EarningsPerShareDiluted_2_Q2_USD":-0.22,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-3595016.0,"NetIncomeLoss_1_Q2_USD":-1030829.0,"NetIncomeLoss_2_Q2_USD":-2671410.0,"StockholdersEquity_0_Q2_USD":4674967.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":12035912.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":12035625.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":12035912.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":12035625.0,"Ticker":"RLMD","CIK":"1553643","name":"RELMADA THERAPEUTICS, INC.","OfficialName":"Relmada Therapeutics Inc. Common Stock","form":"10-Q","period":"20161231","fy":"2017.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"772606380.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20170210"}]